KIORA PHARMACEUTICALS, INC. Amortization of Debt Issuance Costs and Discounts
KIORA PHARMACEUTICALS, INC. (KPRX) reported Amortization of Debt Issuance Costs and Discounts of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2017-02-23
- KIORA PHARMACEUTICALS, INC. amortization of debt issuance costs and discounts for the quarter ending 2016-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. amortization of debt issuance costs and discounts for the quarter ending 2016-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. amortization of debt issuance costs and discounts for the quarter ending 2016-06-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. amortization of debt issuance costs and discounts for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. amortization of debt issuance costs and discounts for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- KIORA PHARMACEUTICALS, INC. amortization of debt issuance costs and discounts for fiscal 2015 was $244.11K, a 8.01% increase from fiscal 2014.
- KIORA PHARMACEUTICALS, INC. amortization of debt issuance costs and discounts for fiscal 2014 was $226.02K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $0.00 derived: sum of 2 quarters · filed 2017-02-23 | $0.00 derived: sum of 3 quarters · filed 2017-02-23 | $0.00 10-K · filed 2017-02-23 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $0.00 derived: sum of 2 quarters · filed 2016-11-01 | $0.00 10-Q · filed 2016-11-01 | $0.00 derived: sum of 4 quarters · filed 2017-02-23 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $0.00 10-Q · filed 2016-08-10 | $0.00 derived: sum of 3 quarters · filed 2017-02-23 | $0.00 derived: sum of 4 quarters · filed 2017-02-23 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-13 | $0.00 derived: sum of 2 quarters · filed 2017-02-23 | $0.00 derived: sum of 3 quarters · filed 2017-02-23 | $0.00 derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $0.00 derived: sum of 2 quarters · filed 2017-02-23 | $0.00 derived: sum of 3 quarters · filed 2017-02-23 | $244.11K 10-K · filed 2017-02-23 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $0.00 derived: sum of 2 quarters · filed 2016-11-01 | $244.11K 10-Q · filed 2016-11-01 | $356.73K derived: sum of 4 quarters · filed 2016-11-01 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $244.11K 10-Q · filed 2016-08-10 | $356.73K derived: sum of 3 quarters · filed 2016-08-10 | $455.73K derived: sum of 4 quarters · filed 2016-08-10 |
| 2015-03-31 | $244.11K 10-Q · filed 2016-05-13 | $356.73K derived: sum of 2 quarters · filed 2016-05-13 | $455.73K derived: sum of 3 quarters · filed 2016-05-13 | |
| 2014-12-31 | $112.62K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $211.62K derived: sum of 2 quarters · filed 2016-03-30 | $226.02K 10-K · filed 2016-03-30 | |
| 2014-09-30 | $99.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $113.40K 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $14.40K 10-Q · filed 2015-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |